Charles River Laboratories International, Inc.
CRL · NYSE
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,005 | $1,032 | $984 | $1,003 |
| % Growth | -2.6% | 4.9% | -1.8% | – |
| Cost of Goods Sold | $666 | $675 | $666 | $718 |
| Gross Profit | $339 | $357 | $318 | $284 |
| % Margin | 33.7% | 34.6% | 32.3% | 28.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $178 | $192 | $178 | $196 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $27 | $65 | $65 | $256 |
| Operating Expenses | $205 | $257 | $243 | $452 |
| Operating Income | $134 | $100 | $75 | -$168 |
| % Margin | 13.3% | 9.7% | 7.6% | -16.7% |
| Other Income/Exp. Net | -$47 | -$29 | -$39 | -$49 |
| Pre-Tax Income | $87 | $71 | $36 | -$217 |
| Tax Expense | $32 | $19 | $10 | -$3 |
| Net Income | $54 | $52 | $25 | -$216 |
| % Margin | 5.4% | 5.1% | 2.6% | -21.5% |
| EPS | 1.11 | 1.06 | 0.5 | -4.22 |
| % Growth | 4.7% | 112% | 111.8% | – |
| EPS Diluted | 1.1 | 1.06 | 0.5 | -4.22 |
| Weighted Avg Shares Out | 49 | 49 | 51 | 51 |
| Weighted Avg Shares Out Dil | 49 | 49 | 51 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $2 |
| Interest Expense | $25 | $30 | $28 | $28 |
| Depreciation & Amortization | $85 | $120 | $120 | $102 |
| EBITDA | $198 | $221 | $184 | -$86 |
| % Margin | 19.7% | 21.4% | 18.7% | -8.6% |